Keyword: AstraZeneca

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

With AstraZeneca's Epanova flopping a key trial, Amarin's Vascepa's is set for an uncontested launch in a likely blockbuster indication.

New FibroGen CEO and former Eli Lilly vet, Enrique Conterno, cleared some existing investor doubts about roxadustat's potential.

In a heated race against GSK in the PARP inhibitor market, AstraZeneca and Merck nabbed a helpful FDA boost for its Lynparza in ovarian cancer.

Epanova's failure to prove a it could cut heart risks could give Amarin's fellow fish oil-derived Vascepa a clearer shot at blockbuster sales.

Problems, both manufacturing and financial, with an Austrian fill-finish firm has resulted in a partial hold of a trial of Innate Pharma.

Enrique Conterno takes the helm at FibroGen as the company and partners prep for the launch of key drug roxadustat.

With a nod in heart failure patients already secured, AstraZeneca's Farxiga has now landed a priority review in patients with or without diabetes.

Daiichi and AZ's Enhertu as well as and Astellas and Seattle Genetics' Padcev won FDA nods as China approved rivals to Prevnar and Gardasil.

Earlier this month, FDA experts voted 7-5 to back Lynparza in pancreatic cancer. But that small majority was enough to convince regulators.